Alexandre Pichard

Oncology, Radiobiology, Cancer Therapy

“It is a great honor to join and to work in a big and respected pharmaceutical company where we strive to improve the state of health of people in the world.”

Your role at Institut Roche and brief presentation of your professional background:

I first joined Institut Roche for one year in 2018 for a
postdoctoral position, and joined again in 2021 as a scientist. I work in a research team that designs and performs scientific preclinical experiments in the context of cancer treatment. Before joining Institut Roche, I evaluated and tried to understand the impact of ionizing radiation on tumor cells, in order to develop new treatments.

My Focus at Institut Roche:

My focus at Institut Roche is to develop new targeted radiotherapies using a particular type of ionizing radiations called alpha particles to fight cancer, particularly for indications for which few treatment options currently exist.

  1. Pouget JP, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, Poty S, Deshayes E, Constanzo J, Bardiès M. From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group’s experience. Nucl Med Biol. 2022.
  2. Karam J, Constanzo J, Pichard A, Gros L, Chopineau J, Morille M, Pouget JP. Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy. Int J Radiat Biol. 2021.
  3. Idrissou MB, Pichard A, Tee B, Kibedi T, Poty S, Pouget JP. Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics. 2021.
  4. Pichard, S Marcatili, R Ladjohounlou, A Courteau, M Jarlier, S Patzke, V Stenberg , P Coopman, G Cartron, A Repetto-Llamazares, H Heyerdahl, I Navarro-Teulon, M Bardiès and JP Pouget: The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020.
  5. R Ladjohounlou, C Lozza, A Pichard, J Constanzo, J Karam, Pe Le Fur, E Deshayes, V Boudousq, S Paillas, M Busson, M Le Blay, M Jarlier, S Marcatili, M Bardiès, F Bruchertseifer, A Morgenstern, J Torgue, I Navarro-Teulon, and JP Pouget. Drugs that modify cholesterol metabolism alter the p38/JNK- mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin Cancer Res. 2019.
  6. Y Ashraf, H Mansouri, V Laurent-Matha, LB Alcaraz, P Roger, S Guiu, D Derocq, G Robin, HA Michaud, H Delpech, M Jarlier, M Pugnière, B Robert, A Puel, L Martin, F Landomiel, T Bourquard, O Achour, I Fruitier-Arnaudin, A Pichard, E Deshayes, A Turtoi, A Poupon, J Simony-Lafontaine, F Boissière-Michot, N Pirot, F Bernex, W Jacot, S du Manoir, C Theillet, JP Pouget, I Navarro-Teulon, N Bonnefoy, A Pèlegrin, T Chardès, P Martineau, E Liaudet-Coopman. Immunotherapy of triple-negative breast cancer with cathepsin D- targeting antibodies. J Immunother Cancer. 2019.
  7. E Deshayes, R Ladjohounlou, P Le Fur, A Pichard, C Lozza, V Boudousq, S Sevestre, M Jarlier, R Kashani, J Koch, J Sosaboski, J Foster, N Chouin, F Bruchertseifer, A Morgenstern, PO Kotzki, I Navarro-Teulon, and JP Pouget. Anti-MISRII radiolabeled antibodies: new tools for a theranostic approach in ovarian cancer. J Nucl Med 2018.
  8. A Maisonial-Besset, T Witkowski, I Navarro-Teulon, O Berthier-Vergnes, G Fois, Y Zhu, S Besse, O Bawa, A Briat, M Quintana, A Pichard, M Bonnet, E Rubinstein, JP Pouget, P Opolon, L Maigne, E Miot-Noirault, JM Chezal, C Boucheix, F Degoul. Tetraspanin 8 (TSPAN 8) as a potential target for radioimmunotherapy of colorectal cancer. Oncotarget. 2017.
  9. P Estupina, A Fontayne, JM Barret, N Kersual, O Dubreuil, M Le Blay, A Pichard, M Jarlier, M Pugnière, M Chauvin, T Chardès, JP Pouget, E Deshayes, A Rossignol, T Abache, C de Romeuf, A Terrier, L Verhaeghe, C Gaucher, JF Prost, A Pèlegrin, I Navarro-Teulon. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget. 2017.
  10. A Pichard, S Marcatili, A Courteau, R Ladjohounlou, I Navarro-Teulon, A Repetto-Llamazares, H Heyerdahl, J Dahle, M Bardiès and JP Pouget. Realistic multi-cellular dosimetry for 177Lu labelled antibodies: model and application. Phys. Med. Biol. 2016.
  11. Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, Sevestre S, Le Blay M, Deshayes E, Sosabowski J, Chardès T, Navarro- Teulon I, Mairs RJ, Pouget JP. Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid Redox Signal. 2016.
  12. Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J. Targeted Cancer Therapy with a Novel Anti- CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non – Hodgkin Lymphoma. PLoS One. 2015.
More publications